关于公司为中实新材料向南京银行申请 1,000 万元融资授信提供担保的公告 共 6 页 证券代码：000931 证券简称：中关村 公告编号：2025-121 北京中关村科技发展（控股）股份有限公司 关于公司为中实新材料向南京银行申请 1,000 万元融资授信 提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 10 月 28 日召开第九届董事会 2025 年度第六次临时会议，审议通过《关于公司 为中实新材料向南京银行申请 1,000 万元融资授信提供担保的议案》，具体情况 如下： 一、担保情况概述 经银行选定的深圳市国策房地产土地资产评估有限公司对上述 72 个车位房 地产进行评估并出具编号为深国策估字 FBJ[2025]100021 号的《房地产抵押估价 1 关于公司为中实新材料向南京银行申请 1,000 万元融资授信提供担保的公告 共 6 页 报告》：上述房地产于价值时点 2025 年 9 月 8 日的抵押价值为 2,522.94 万元人 民币。 经银行选定的中安盛世（北 ...

关于取消监事会并修订《公司章程》和修订、制定及废止公司部分治理制度的公告 共 46 页 证券代码：000931 证券简称：中关村 公告编号：2025-119 北京中关村科技发展（控股）股份有限公司 关于取消监事会并修订《公司章程》和修订、制定及废止 公司部分治理制度的公告 根据《中华人民共和国公司法》（以下简称：《公司法》）和《上市公司章 程指引》《深圳证券交易所股票上市规则》等相关法律、行政法规、规范性文件 的规定，结合公司的实际情况，公司决定取消监事会，取消监事设置，《公司法》 中规定的监事会职权由董事会审计委员会承接，公司《监事会议事规则》等监事 会相关制度相应废止，相关制度中涉及监事的表述相应删除，同时修订《公司章 程》。公司现任监事将自公司股东会审议通过取消监事会及修订《公司章程》事 项之日起解除监事职务。 在公司股东会审议通过取消监事会设置事项前，公司第九届监事会及监事仍 将严格按照《公司法》《公司章程》等相关规定的要求，勤勉尽责履行监督职能， 对公司经营成果、财务状况及董事、高级管理人员履职的合法合规性进行监督， 维护公司和全体股东的利益。 1 关于取消监事会并修订《公司章程》和修订、制定及废止 ...

关于终止下属公司对外投资设立全资子公司的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-122 北京中关村科技发展（控股）股份有限公司 关于终止下属公司对外投资设立全资子公司的公告 上述投资事项尚未实际开展，公司终止对外投资事项不会对公司生产经营及 财务状况等产生重大影响，不存在损害公司及全体股东特别是中小股东利益的情 形。 四、备查文件 1、第九届董事会 2025 年度第六次临时会议决议。 1 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 10 月 28 日召开第九届董事会 2025 年度第六次临时会议，审议通过《关于终止 下属公司对外投资设立全资子公司的议案》，具体情况如下： 一、对外投资概述 公司于 2025 年 4 月 28 日召开第九届董事会 2025 年度第二次临时会议，审 议通过《关于下属公司对外投资设立全资子公司的议案》，公司全资子公司北京 中关村四环医药开发有限责任公司之全资子公司山东华素健康护理品有限公司 拟以自有资金 100 万元人 ...

证券代码：000931 证券简称：中关村 公告编号：2025-120 关于公司为四环医药向南京银行申请 7,000 万元融资授信提供担保的公告 共 5 页 北京中关村科技发展（控股）股份有限公司 关于公司为四环医药向南京银行申请 7,000 万元融资授信 提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 10 月 28 日召开第九届董事会 2025 年度第六次临时会议，审议通过《关于公司 为四环医药向南京银行申请 7,000 万元融资授信提供担保的议案》，具体情况如 下： 一、担保情况概述 经第八届董事会 2024 年度第十一次临时会议、2024 年第五次临时股东会审 议通过，公司全资子公司北京中关村四环医药开发有限责任公司（以下简称：四 环医药）向南京银行股份有限公司北京分行（以下简称：南京银行）申请额度不 超过 7,000 万元人民币的融资授信，授信期限为 1 年，公司以其部分综合、地下 库房、地下车位等用途房地产以及分摊的土地使用权提供抵押担保，并提供连带 责任保证担 ...

证券代码：000931 证券简称：中关村 公告编号：2025-123 北京中关村科技发展（控股）股份有限公司 关于召开 2025 年第七次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 关于召开 2025 年第七次临时股东会的通知 共 6 页 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 联网投票系统投票的具体时间为 2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 11 日 7、出席对象： （1）在股权登记日持有公司股份的普通股股东或其代理人。 1、股东会届次：2025 年第七次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市 ...

证券代码：000931 证券简称：中关村 公告编号：2025-117 第九届监事会 2025 年度第二次临时会议决议公告 共 2 页 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届监事 会 2025 年度第二次临时会议通知于 2025 年 10 月 22 日以专人送达、电子邮件或 传真等方式发出，会议于 2025 年 10 月 28 日下午 14 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场表决方式如期召开。会议应到监事 3 名，实到监事 3 名。会议召开程序符合相关法律法规和《公司章程》的有关规定。 经与会监事认真讨论研究，形成以下决议： 一、审议通过《2025 年第三季度报告》； 北京中关村科技发展（控股）股份有限公司 第九届监事会 2025 年度第二次临时会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 监事会在全面了解、审核公司 2025 年第三季度报告后，发表如下审核意见： 经审核，监事会认为董事会编制和审议的公司 2025 年第三季度报告的程序 符合法律、行政法规及中国证监会的规定，报告 ...

第九届董事会 2025 年度第六次临时会议决议公告 共 5 页 具体内容详见与本公告同日披露的《2025 年第三季度报告》（公告编号： 2025-118）。 证券代码：000931 证券简称：中关村 公告编号：2025-116 北京中关村科技发展（控股）股份有限公司 第九届董事会 2025 年度第六次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届董事 会 2025 年度第六次临时会议通知于 2025 年 10 月 22 日以专人送达、电子邮件或 传真等方式发出，会议于 2025 年 10 月 28 日上午 10 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场结合通讯表决方式如期召开。会议应 到董事 9 名，实到董事 9 名。会议召开程序符合相关法律法规和《公司章程》的 有关规定。经与会董事认真讨论研究，形成以下决议： 一、审议通过《2025 年第三季度报告》； 表决结果：9 票同意，0 票反对，0 票弃权。 全体参会董事审议通过公司《2025 年第 ...

Core Insights - The company reported a third-quarter revenue of 644 million, representing a decline of 1.96% [1] - The net profit for the third quarter was 10.68 million, down 29.90% [1] - For the first three quarters, the total revenue was 1.882 billion, a decrease of 2.46% [1] - The net profit for the first three quarters amounted to 49.49 million, reflecting a decline of 4.14% [1]

Financial Performance - The company's revenue for Q3 2025 was ¥643,647,540.63, a decrease of 1.96% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥10,682,468.20, down 29.90% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was ¥6,789,290.78, a decline of 47.83% compared to the previous year[5]. - The operating cash flow for the year-to-date period was ¥23,256,149.48, reflecting a significant decrease of 70.82%[5]. - Total operating revenue for the current period is ¥1,882,462,548.88, a decrease of 2.45% compared to ¥1,929,843,801.69 in the previous period[58]. - Net profit for the current period is ¥61,253,540.39, a decline of 5.56% from ¥64,653,431.11 in the previous period[59]. - Operating profit decreased to ¥84,829,692.12, down 13.83% from ¥98,472,510.51 in the previous period[59]. - Basic and diluted earnings per share decreased to ¥0.0657 from ¥0.0686 in the previous period[59]. - The company’s total profit for the current period is ¥83,895,528.42, down from ¥101,956,515.35 in the previous period[59]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,816,126,330.76, an increase of 2.80% from the end of the previous year[5]. - Total current assets increased to ¥1,741,012,968.26 from ¥1,608,572,076.75, reflecting a growth of approximately 8.2%[54]. - Current liabilities decreased slightly to ¥1,370,362,290.32 from ¥1,379,633,066.20, a reduction of approximately 0.2%[55]. - The company reported a total equity of ¥1,866,496,118.04, an increase from ¥1,806,997,755.53, representing a growth of about 3.3%[57]. - The company’s cash and cash equivalents rose to ¥187,951,511.04 from ¥151,393,279.42, marking an increase of approximately 24.2%[54]. - The company’s inventory decreased to ¥202,070,061.15 from ¥214,338,468.42, a decline of about 5.7%[54]. - The company’s retained earnings improved to -¥746,876,506.23 from -¥796,367,861.42, reflecting a positive change of approximately 6.2%[57]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 68,039[11]. - The largest shareholder, Gome Holdings Group Co., Ltd., holds 24.71% of shares, totaling 186,113,207 shares[11]. - Gome Electrical Appliances Co., Ltd. holds 6.64% of shares, totaling 50,000,000 shares[11]. - The number of shares pledged by Gome Holdings Group is 111,601,400, with 182,466,343 shares frozen[12]. - Gome Holdings has pledged 111,601,400 shares, accounting for 59.96% of its holdings, which represents 14.82% of the company's total share capital[16]. - Gome Electrical Appliances has 50,000,000 shares pledged, which is 100% of its holdings, representing 6.64% of the company's total share capital[16]. - The total number of shares under judicial freeze for both Gome Holdings and Gome Electrical Appliances is 172,903,529 shares, representing 73.23% of their total holdings and 22.96% of the company's total share capital[17]. - Gome Holdings has 59,562,814 shares under cumulative pending freeze, which is 32.00% of its holdings and 7.91% of the company's total share capital[18]. - The total number of shares under pending freeze for Gome Electrical Appliances is 2,709,313,426 shares, which is 5,418.63% of its holdings and 359.74% of the company's total share capital[18]. Corporate Governance - The company completed the election of the ninth board of directors and the supervisory board on January 23, 2025[13]. - The new president appointed is Hou Zhajun, along with several vice presidents[14]. - The independent director Dong Lei will no longer serve after the board transition[14]. - The company has established various specialized committees within the new board, including an audit committee and a strategic committee[14]. - The company has no changes in the top 10 shareholders due to securities lending activities[13]. Product Development and Regulatory Approvals - Beijing Huasu received the acceptance notice for the consistency evaluation application of Tramadol Hydrochloride Tablets (50mg), marking the entry into the review stage[30]. - Dodo Pharmaceutical's Eleutherococcus Injection was selected in the national traditional Chinese medicine procurement alliance, with a winning price of 13.18 RMB per 20ml vial[31]. - The procurement cycle for the selected Eleutherococcus Injection lasts until December 31, 2027, which may enhance market coverage and brand influence[32]. - Beijing Huasu's production license was updated to include the production of raw material drug Benzyl Benzoate, enhancing production capacity and compliance with GMP standards[33][34]. - Beijing Huasu's Hydroxycodone Controlled-Release Tablets (40mg) received acceptance for market registration, entering the review phase[37]. - Zhongshi New Materials and Shandong Huasu Health Care Products both received high-tech enterprise certificates, allowing for a reduced corporate income tax rate of 15% for three years[36]. - Duoduo Pharmaceutical's application for the marketing authorization of Bromhexine Hydrochloride Injection (2ml:4mg) has been accepted by the National Medical Products Administration, marking the start of the review phase[38]. - Beijing Huasu's Naloxone Injection (1ml:1mg) has been selected in the 10th batch of national centralized drug procurement, with a winning price of 0.99 RMB per unit, which will enhance the company's market presence and sales channels[39][40]. - Shandong Huasu's application for the marketing authorization of Bisoprolol Amlodipine Tablets (5mg each) has been accepted, indicating progress in the product's market competitiveness[41]. - Duoduo Pharmaceutical's Tramadol Hydrochloride Injection (2ml:100mg) has passed the consistency evaluation for generic drugs, which will positively impact the company's operational performance[46]. - The acceptance of multiple drug applications by the National Medical Products Administration indicates a strategic focus on expanding the product portfolio and enhancing market competitiveness[38][41][44].

Core Viewpoint - Zhongguancun Technology Development (Holding) Co., Ltd. has received a warning letter from the Beijing Securities Regulatory Bureau due to issues related to revenue and cost recognition, improper handling of sales commissions, and inaccuracies in financial accounting for rent reductions, which have led to inaccurate financial disclosures in annual reports [1] Group 1: Regulatory Issues - The company has been found to have deficiencies in governance, including flaws in meeting records and untimely revisions of certain systems [1] - Key executives, including the chairman, general manager, and CFO, are held primarily responsible for the violations of the Information Disclosure Management Measures [1] Group 2: Shareholder Information - Gome Electrical Appliances Co., Ltd., a significant shareholder, has had 16,068,053 shares (32.14% of its holdings) frozen by the Haikou City Longhua District People's Court for a period of 36 months [2] - The company asserts that the frozen shares will not lead to a change in control and that there are no non-operational fund occupations or illegal guarantees harming the company's interests [2] Group 3: Financial Performance - For the first half of 2025, the company reported a revenue of 1.239 billion yuan, a year-on-year decrease of 2.71%, while the net profit attributable to shareholders increased by 6.65% to 38.81 million yuan [3] - As of October 29, the company's stock price fell by 2.62% to 5.21 yuan per share, with a total market capitalization of 3.92 billion yuan [3]